New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 4, 2014
09:19 EDTGSK, PTXClosing of Pernix transaction to acquire Treximet tablets from GSK delayed
Pernix Therapeutics Holdings (PTX) announced that the closing of its transaction to acquire the U.S. rights to Treximet for the acute treatment of migraine attacks with or without aura in adults has been delayed due to a short-term supply constraint for the product. The company is working with GlaxoSmithKline (GSK) to ensure sufficient supply to meet anticipated demand. The company and its lenders are also performing additional due diligence related to this supply issue. Doug Drysdale, Chairman, President and CEO of Pernix said, “We are working with our lenders to complete our review and remain optimistic about our ability to close the acquisition of Treximet. We hope to complete our due diligence and the financing necessary in the near future.”
News For PTX;GSK From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 27, 2015
08:00 EDTGSKGlaxo has cut 40% of China sales reps in wake of scandal, Reuters reports
Subscribe for More Information
07:34 EDTGSKGlaxoSmithKline starts phase III study of sirukumab in Giant Cell Arteritis
Subscribe for More Information
November 25, 2015
11:29 EDTGSKStudy says Valeant, others exploding dermatology drug prices, WSJ reports
The JAMA Dermatology journal published a new study that found that retail prices of 19 dermatologic prescription drugs increased fivefold on average between 2009 and 2015, reported The Wall Street Journal. Targretin, marketed by Valeant (VRX), jumped to $30,320 this year from $15,708 last year and $1,687 in 2009, the study found, but "It's not just Valeant," said lead author Miranda Rosenberg. Prices for drugs made by GlaxoSmithKline (GSK) and Novartis (NVS) at least doubled or tripled over the same time frame, the report noted. Reference Link
November 24, 2015
11:16 EDTGSKAdaptimmune initiates Phase I/II trial of affinity enhanced T-cell therapy
Subscribe for More Information
November 23, 2015
08:08 EDTGSKIdera Pharmaceuticals announces partnership with GSK
Idera Pharmaceuticals (IDRA) announced it has entered into an exclusive worldwide collaboration and license agreement with GSK (GSK) to research, develop and commercialize selected molecules from Idera's 3rd generation antisense platform for the treatment of selected targets in renal disease. Under the terms of the agreement, Idera is eligible to receive approximately $100M in development and regulatory milestone payments, including a $2.5M upfront payment. Additionally, Idera is eligible to receive royalties on all sales upon commercialization at varying rates up to five percent on annual net sales in excess of $500M.
November 18, 2015
08:11 EDTGSKIMS Health forecasts global drug spending to increase 30% by 2020 to $1.4T
Subscribe for More Information
November 16, 2015
07:22 EDTPTXBrean Capital to hold a summit
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use